Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.

Thomas BlevinsQianyi ZhangJuan Pablo FriasHideaki JinnouchiAnnette M Changnull null

Published in: Diabetes care (2020)

URLi compared with lispro in a basal-bolus regimen was confirmed to be noninferior for HbA1c and superior to lispro for PPG control in patients with type 2 diabetes.

Keyphrases

double blind
clinical trial
placebo controlled
phase ii
phase iii
open label
study protocol
high resolution
randomized controlled trial
mass spectrometry